bupropion has been researched along with Apoplexy in 6 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In 2011, the US Food and Drug Administration requested that GlaxoSmithKline perform retrospective adjudication of cardiovascular (CV) events reported in the bupropion drug-development trials for smoking cessation." | 7.85 | Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. ( Ascher, J; Hasselblad, V; Huang, M; Kittle, J; Kolls, BJ; Krishen, A; Lopes, RD; Mahaffey, KW; Marquess, ML; McGuire, DK; Roe, MT; Russell, SD; Wilson, MD, 2017) |
| "To investigate whether varenicline is associated with an increased risk of serious cardiovascular events compared with another drug used for smoking cessation, bupropion." | 7.78 | Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2012) |
| "To calculate incremental cost-utility ratios (cost per quality-adjusted life-year [QALY] gained) for bupropion (Zyban; GlaxoSmithKline; Gothenburg, Sweden), as compared to nicotine replacement therapy (NRT) in smoking cessation programs for a follow-up period of 20 years." | 7.73 | The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. ( Bolin, K; Lindgren, B; Willers, S, 2006) |
| "In 2011, the US Food and Drug Administration requested that GlaxoSmithKline perform retrospective adjudication of cardiovascular (CV) events reported in the bupropion drug-development trials for smoking cessation." | 3.85 | Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. ( Ascher, J; Hasselblad, V; Huang, M; Kittle, J; Kolls, BJ; Krishen, A; Lopes, RD; Mahaffey, KW; Marquess, ML; McGuire, DK; Roe, MT; Russell, SD; Wilson, MD, 2017) |
| " The aim of this study was to compare the direct medical costs of smoking cessation therapies with varenicline, bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua over 5 time horizons: 2, 5, 10, and 20 years, and lifetime." | 3.78 | Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua. ( Cuesta, G; Lovato, P; Lutz, MA, 2012) |
| "To investigate whether varenicline is associated with an increased risk of serious cardiovascular events compared with another drug used for smoking cessation, bupropion." | 3.78 | Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2012) |
| "To calculate incremental cost-utility ratios (cost per quality-adjusted life-year [QALY] gained) for bupropion (Zyban; GlaxoSmithKline; Gothenburg, Sweden), as compared to nicotine replacement therapy (NRT) in smoking cessation programs for a follow-up period of 20 years." | 3.73 | The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. ( Bolin, K; Lindgren, B; Willers, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Parikh, NS | 1 |
| Salehi Omran, S | 1 |
| Kamel, H | 1 |
| Elkind, MSV | 1 |
| Willey, JZ | 1 |
| Kittle, J | 1 |
| Lopes, RD | 1 |
| Huang, M | 1 |
| Marquess, ML | 1 |
| Wilson, MD | 1 |
| Ascher, J | 1 |
| Krishen, A | 1 |
| Hasselblad, V | 1 |
| Kolls, BJ | 1 |
| Roe, MT | 1 |
| McGuire, DK | 1 |
| Russell, SD | 1 |
| Mahaffey, KW | 1 |
| Langley, TE | 1 |
| Szatkowski, L | 1 |
| McNeill, A | 1 |
| Coleman, T | 1 |
| Lewis, S | 1 |
| Lutz, MA | 1 |
| Lovato, P | 1 |
| Cuesta, G | 1 |
| Svanström, H | 1 |
| Pasternak, B | 1 |
| Hviid, A | 1 |
| Bolin, K | 1 |
| Lindgren, B | 1 |
| Willers, S | 1 |
1 review available for bupropion and Apoplexy
| Article | Year |
|---|---|
Smoking-cessation pharmacotherapy for patients with stroke and TIA: Systematic review.
Topics: Bupropion; Female; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Randomized Co | 2020 |
5 other studies available for bupropion and Apoplexy
| Article | Year |
|---|---|
Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort.
Topics: Adult; Bupropion; Cardiotoxicity; Cardiovascular Diseases; Drug Discovery; Female; Humans; Male; Mid | 2017 |
Prescribing of nicotine replacement therapy to cardiovascular disease patients in England.
Topics: Adult; Benzazepines; Bupropion; Coronary Disease; Drug Prescriptions; England; General Practice; Hum | 2012 |
Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
Topics: Adolescent; Adult; Aged; Benzazepines; Bupropion; Coronary Disease; Costs and Cost Analysis; Dopamin | 2012 |
Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.
Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Benzazepines; Bupropion; Cardiovascular Dise | 2012 |
The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
Topics: Adult; Aged; Bupropion; Chewing Gum; Cost-Benefit Analysis; Dopamine Uptake Inhibitors; Female; Hear | 2006 |